Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CVD-Cog trial of isosorbide mononitrate and cilostazol after cortical or large subcortical stroke/TIA with cerebral small vessel disease
ISRCTN14632228Phase 2Recruiting
- Sponsor
- University of Nottingham
- Start
- Dec 2025
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, open-label trial of isosorbide mononitrate and cilostazol in Cerebral Small Vessel Disease (CSVD), ischemic stroke and transient ischaemic attack (TIA) (5 arms), sponsored by University of Nottingham. Primary endpoint: Feasibility. Started Dec 2025; status: recruiting.
02
Drugs
isosorbide mononitratecilostazol
03
Conditions
Cerebral Small Vessel Disease (CSVD)ischemic stroketransient ischaemic attack (TIA)
Beyond the preview
Go deeper on ISRCTN14632228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN14632228.